文献速递脑血管病神经重症与神经感染

可溶性细胞间黏附分子-1与FAST试验中脑出血结局的关联

Association Between Soluble Intercellular Adhesion Molecule-1 and Intracerebral Hemorrhage Outcomes in the FAST Trial.
PubMed 文献 · Stroke · 2023-05-25

本研究为FAST试验的事后二次分析,纳入507例脑出血患者,探讨入院血清sICAM-1水平与90天死亡、不良结局及影像学结局的关联。多变量分析显示sICAM-1每升高1个标准差与死亡(OR 1.53)、不良结局(OR 1.34)及血肿扩大(OR 1.35)相关,但与72小时血肿周围水肿扩大无关。

要点

  • 入院sICAM-1每升高1个标准差,90天死亡风险OR 1.53(95%CI 1.15-2.03)。
  • sICAM-1与90天不良结局相关,OR 1.34(95%CI 1.06-1.69)。
  • sICAM-1与24小时血肿扩大相关,OR 1.35(95%CI 1.11-1.66)。

核心结论

  • 入院血清sICAM-1水平与死亡、不良结局及血肿扩大相关。
  • 鉴于重组活化凝血因子VII与sICAM-1之间可能存在生物学交互作用,这些发现强调需进一步探索sICAM-1作为脑出血不良结局潜在标志物的作用。

研究设计与样本

  • 对观察性队列进行事后二次分析,使用FAST试验(因子VII治疗急性出血性卒中试验)的数据。
  • 共841例患者中纳入507例(60%)具有完整数据的患者。
  • 暴露为入院血清sICAM-1水平;共同主要结局为90天死亡和不良结局(改良Rankin量表评分4-6分)。
  • 次要影像学结局为24小时血肿扩大和72小时血肿周围水肿扩大。
  • 采用多元线性回归和逻辑回归分析,校正人口学特征、脑出血严重程度特征、最初24小时收缩压变化、治疗随机分组及从症状发作到研究药物给药的时间。

主要发现

  • 血肿扩大发生于169例(33%),242例(48%)出现不良结局。
  • 多变量分析中,sICAM-1与死亡相关(比值比1.53每标准差增加[95%CI 1.15-2.03])。
  • sICAM-1与不良结局相关(比值比1.34每标准差增加[95%CI 1.06-1.69])。
  • sICAM-1与血肿扩大相关(比值比1.35每标准差增加[95%CI 1.11-1.66]),但与72小时血肿周围水肿扩大的对数转换值无关。
  • 按治疗分组分层分析中,重组活化凝血因子VII组结果相似,安慰剂组未见类似结果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neutrophil-mediated inflammation in the acute phase of intracerebral hemorrhage (ICH) worsens outcome in preclinical studies. sICAM-1 (soluble intercellular adhesion molecule-1), an inducible ligand for integrins and cell-cell adhesion molecules, is critical for neutrophil extravasation. We aimed to determine whether serum levels of sICAM-1 are associated with worse outcomes after ICH. METHODS: We conducted a post hoc secondary analysis of an observational cohort using data from the FAST trial (Factor-VII for Acute Hemorrhagic Stroke Treatment). The study exposure was the admission serum level of sICAM-1. The coprimary outcomes were mortality and poor outcome (modified Rankin Scale score 4-6) at 90 days. Secondary radiological outcomes were hematoma expansion at 24 hours and perihematomal edema expansion at 72 hours. We used multiple linear and logistic regression analyses to test for associations between sICAM-1 and outcomes, after adjustment for demographics, ICH severity characteristics, change in the systolic blood pressure in the first 24 hours, treatment randomization arm, and the time from symptom onset to study drug administration. RESULTS: Of 841 patients, we included 507 (60%) with complete data. Hematoma expansion occurred in 169 (33%), while 242 (48%) had a poor outcome. In multivariable analyses, sICAM-1 was associated with mortality (odds ratio, 1.53 per SD increase [95% CI, 1.15-2.03]) and poor outcome (odds ratio, 1.34 per SD increase [CI, 1.06-1.69]). In multivariable analyses of secondary outcomes, sICAM-1 was associated with hematoma expansion (odds ratio, 1.35 per SD increase [CI, 1.11-1.66]), but was not associated with log-transformed perihematomal edema expansion at 72 hours. In additional analyses stratified by treatment assignment, similar results were noted in the recombinant activated factor-VII arm, but not in the placebo arm. CONCLUSIONS: Admission serum levels of sICAM-1 were associated with mortality, poor outcome, and hematoma expansion. Given the possibility of a biological interaction between recombinant activated factor-VII and sICAM-1, these findings highlight the need to further explore the role of sICAM-1 as a potential marker of poor ICH outcomes.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Witsch J, Roh D, Oh S, et al. Association Between Soluble Intercellular Adhesion Molecule-1 and Intracerebral Hemorrhage Outcomes in the FAST Trial. Stroke. 2023. PMID: 37226773. doi:10.1161/STROKEAHA.123.042466

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。